Skip to main navigation
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Contact
  • Programs
    • HBV
    • Pipeline
  • Patients
    • Commitment
    • Clinical Trials
    • Resources
  • Sustainability
    • Overview
    • Business Ethics
    • Access to Health Care
    • Human Capital
    • Environment, Health and Safety
  • Collaborations
  • Investors
    • News & Events
    • Corporate Governance
    • Financials & Filings
    • Stock Information
  • Careers
    • Culture
    • Benefits
    • Opportunities
On the
  • Press Releases
  • Events & Presentations

Event Details

EASL 2018 Paris

Apr 12, 2018

Supporting Materials

EASL 2018, Paris, France, “Interim Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM), in Healthy Volunteers and Non-Cirrhotic Viremic Subjects with Chronic Hepatitis B” 2 MB
Shareholder Tools Print Email Alerts Printed Materials RSS News Feeds
Search Investors

Contact Us

833.509.4583
info@assemblybio.com
About Programs Patients Collaborations Investors Careers

© 2021 Assembly Biosciences, Inc.